Home » Stocks » NRBO

NeuroBo Pharmaceuticals, Inc. (NRBO)

Stock Price: $3.23 USD -0.46 (-12.47%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $3.27 +0.04 (1.24%) Apr 16, 5:40 PM
Market Cap 71.61M
Revenue (ttm) n/a
Net Income (ttm) -29.68M
Shares Out 22.17M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $3.23
Previous Close $3.69
Change ($) -0.46
Change (%) -12.47%
Day's Open 3.62
Day's Range 3.19 - 3.67
Day's Volume 107,544
52-Week Range 3.19 - 15.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapi...

2 days ago - PRNewsWire

Wall Street recommends buying shares of NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) and Windtree Therapeutics Inc (NASDAQ:WINT), even though these two securities have shown poor performance over the prior...

Other stocks mentioned: WINT
1 week ago - GuruFocus

BOSTON, March 24, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Continge...

3 weeks ago - PRNewsWire

BOSTON, Jan. 21, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of a...

2 months ago - PRNewsWire

BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a priva...

3 months ago - PRNewsWire

NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

3 months ago - Zacks Investment Research

BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...

5 months ago - PRNewsWire

BOSTON, Aug. 11, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.

8 months ago - PRNewsWire

BOSTON, June 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...

10 months ago - PRNewsWire

About NRBO

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquart... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
NRBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for NRBO stock is "Buy" and the 12-month stock price forecast is 16.00.

Price Target
$16.00
Analyst Consensus: Buy